212 related articles for article (PubMed ID: 7783568)
21. Multidrug resistance is more than MDR1 activity.
Preisler HD
Leuk Res; 1995 Jul; 19(7):429-31. PubMed ID: 7637388
[No Abstract] [Full Text] [Related]
22. Is resistance useless? Multidrug resistance and collateral sensitivity.
Hall MD; Handley MD; Gottesman MM
Trends Pharmacol Sci; 2009 Oct; 30(10):546-56. PubMed ID: 19762091
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
24. Drug-stimulated ATPase activity of the human P-glycoprotein.
Scarborough GA
J Bioenerg Biomembr; 1995 Feb; 27(1):37-41. PubMed ID: 7629050
[TBL] [Abstract][Full Text] [Related]
25. The molecular mysteries underlying P-glycoprotein-mediated multidrug resistance.
Szakács G; Chen KG; Gottesman MM
Cancer Biol Ther; 2004 Apr; 3(4):382-4. PubMed ID: 14976423
[No Abstract] [Full Text] [Related]
26. Mutations to amino acids located in predicted transmembrane segment 6 (TM6) modulate the activity and substrate specificity of human P-glycoprotein.
Loo TW; Clarke DM
Biochemistry; 1994 Nov; 33(47):14049-57. PubMed ID: 7947814
[TBL] [Abstract][Full Text] [Related]
27. Unanswered questions about multidrug resistance.
Beck WT
Cytotechnology; 1996; 19(3):177-9. PubMed ID: 8862003
[No Abstract] [Full Text] [Related]
28. Clinical relevance of P-glycoprotein in drug therapy.
Lin JH; Yamazaki M
Drug Metab Rev; 2003 Nov; 35(4):417-54. PubMed ID: 14705869
[TBL] [Abstract][Full Text] [Related]
29. miR-138 might reverse multidrug resistance of leukemia cells.
Zhao X; Yang L; Hu J; Ruan J
Leuk Res; 2010 Aug; 34(8):1078-82. PubMed ID: 19896708
[TBL] [Abstract][Full Text] [Related]
30. P-glycoprotein and multidrug resistance.
Gottesman MM; Pastan I; Ambudkar SV
Curr Opin Genet Dev; 1996 Oct; 6(5):610-7. PubMed ID: 8939727
[TBL] [Abstract][Full Text] [Related]
31. [Molecular mechanisms of chemotherapeutic resistance in genitourinary cancers].
Kakehi Y
Nihon Hinyokika Gakkai Zasshi; 1998 Jan; 89(1):1-13. PubMed ID: 9493416
[No Abstract] [Full Text] [Related]
32. Genetics of drug resistance.
Biedler JL; Spengler BA
Cancer Treat Res; 1994; 73():1-16. PubMed ID: 7710901
[No Abstract] [Full Text] [Related]
33. Kinetics of the P-glycoprotein, the multidrug transporter.
Stein WD
Exp Physiol; 1998 Mar; 83(2):221-32. PubMed ID: 9568482
[No Abstract] [Full Text] [Related]
34. Expression of P-glycoprotein in normal and malignant rat liver cells.
Lee CH; Bradley G; Ling V
Cold Spring Harb Symp Quant Biol; 1994; 59():607-15. PubMed ID: 7587120
[No Abstract] [Full Text] [Related]
35. Reversal of multidrug resistance in hematological malignancies.
Vossebeld PJ; Sonneveld P
Blood Rev; 1999 Jun; 13(2):67-78. PubMed ID: 10414943
[No Abstract] [Full Text] [Related]
36. Structural and functional aspects of P-glycoproteins and related transport proteins.
Lepage P; Gros P
Curr Opin Nephrol Hypertens; 1993 Sep; 2(5):735-43. PubMed ID: 7522912
[TBL] [Abstract][Full Text] [Related]
37. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
38. Cloning, transfer, and characterization of multidrug resistance protein.
Grant CE; Bhardwaj G; Cole SP; Deeley RG
Methods Enzymol; 1998; 292():594-607. PubMed ID: 9711585
[No Abstract] [Full Text] [Related]
39. Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet.
Qu Q; Sharom FJ
Biochemistry; 2002 Apr; 41(14):4744-52. PubMed ID: 11926837
[TBL] [Abstract][Full Text] [Related]
40. Multidrug resistance in cancer chemotherapy.
Patel NH; Rothenberg ML
Invest New Drugs; 1994; 12(1):1-13. PubMed ID: 7960599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
